Invasive Aspergillosis in solid‐organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice
Top Cited Papers
- 21 March 2019
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 33 (9), e13544
- https://doi.org/10.1111/ctr.13544
Abstract
These updated AST-IDCOP guidelines provide information on epidemiology, diagnosis, and management of Aspergillus after organ transplantation. Aspergillus is the most common invasive mold infection in solid-organ transplant (SOT) recipients, and it is the most common invasive fungal infection among lung transplant recipients. Time from transplant to diagnosis of invasive aspergillosis (IA) is variable, but most cases present within the first year post-transplant, with shortest time to onset among liver and heart transplant recipients. The overall 12-week mortality of IA in SOT exceeds 20%; prognosis is worse among those with central nervous system involvement or disseminated disease. Bronchoalveolar lavage galactomannan is preferred for the diagnosis of IA in lung and non-lung transplant recipients, in combination with other diagnostic modalities (eg, chest CT scan, culture). Voriconazole remains the drug of choice to treat IA, with isavuconazole and lipid formulations of amphotericin B regarded as alternative agents. The role of combination antifungals for primary therapy of IA remains controversial. Either universal prophylaxis or preemptive therapy is recommended in lung transplant recipients, whereas targeted prophylaxis is favored in liver and heart transplant recipients. In these guidelines, we also discuss newer antifungals and diagnostic tests, antifungal susceptibility testing, and special patient populations.Keywords
Funding Information
- American Society of Transplantation
This publication has 246 references indexed in Scilit:
- Evaluation of MycAssay™ Aspergillus for Diagnosis of Invasive Pulmonary Aspergillosis in Patients without Hematological CancerPLOS ONE, 2013
- Comparison of Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch in Immunocompromised Children and Healthy AdultsAntimicrobial Agents and Chemotherapy, 2011
- In Vitro Echinocandin Susceptibility of Aspergillus Isolates from Patients Enrolled in the Transplant-Associated Infection Surveillance NetworkAntimicrobial Agents and Chemotherapy, 2011
- Comparison of an Aspergillus Real-time Polymerase Chain Reaction Assay With Galactomannan Testing of Bronchoalvelolar Lavage Fluid for the Diagnosis of Invasive Pulmonary Aspergillosis in Lung Transplant RecipientsClinical Infectious Diseases, 2011
- Bioavailability and Population Pharmacokinetics of Voriconazole in Lung Transplant RecipientsAntimicrobial Agents and Chemotherapy, 2010
- Factors Associated with Mortality in Transplant Patients with Invasive AspergillosisClinical Infectious Diseases, 2010
- Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazoleJournal of the American Academy of Dermatology, 2010
- Impact of Mold Infections in Explanted Lungs on Outcomes of Lung TransplantationTransplantation, 2010
- Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenationJournal of Antimicrobial Chemotherapy, 2009
- Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating FactorThe New England Journal of Medicine, 1992